Christopher H. Lieu

University of Colorado Cancer Center — United States

Medicine · Health Sciences

43h-index10.3kcitations395works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(138), Genetic factors in colorectal cancer(77), Cancer Immunotherapy and Biomarkers(74), Cancer Genomics and Diagnostics(57), Colorectal Cancer Surgical Treatments(47)

Publications392 total

Inferring optimal detection of <i>MTAP</i> homozygous loss (homozygous deletion) in pancreatic cancer: Association with treatment exposure, co-alterations, site of biopsy, and clinical outcomes.
Journal of Clinical Oncology·2026
Real-world survival and responses to HER2 directed treatment in gastrointestinal cancers based on HER2 non-amplified mutation and HER2 amplification/overexpression status.
Journal of Clinical Oncology·2026
A novel framework to grade the quality of surrogate endpoints at the trial level: An analysis of surrogate endpoints used in colorectal cancer trials.
Journal of Clinical Oncology·2026
Survival and treatment trends in BRCA-mutated metastatic pancreatic adenocarcinoma.
Journal of Clinical Oncology·2026
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-North America).
Journal of Clinical Oncology·2026
Artificial intelligence (AI) as a decision support tool for practicing oncologists: Gastrointestinal (GI) cancer cases.
Journal of Clinical Oncology·2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal
Journal of Clinical Oncology·2026Open Access
The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy
Cancer Cell·2026Open Access
A Fluorescence Resonance Energy Transfer-Based Assay Targeting Tumor-Derived Extracellular Vesicles for Highly Specific Pancreatic Cancer Detection
ACS Nano·2025
Supplementary Figure S2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Protocol from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Supplementary Figure S3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Supplementary Table 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
2025Open Access
page 1 of 20Next →

Frequent Co-authors

Scott Kopetz(16), Carmen J. Allegra(9), Cathy Eng(8), Stanley R. Hamilton(8), Daniel J. Sargent(7), Al B. Benson(6), Howard S. Höchster(6), Wells A. Messersmith(6), Emily K. Bergsland(5), Van K. Morris(5), Michael J. Overman(5), Jordan Berlin(5), Luis A. Díaz(5), Antonia R. Sepulveda(5), Wayne W. Grody(5), Allison M. Cushman‐Vokoun(5), William K. Funkhouser(5), Noralane M. Lindor(5), Bruce D. Minsky(5), Federico A. Monzon(5)